Investigational drug · Phase 3
AD109
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for OSA.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
0 still active
All registered trials
8
Any phase or sponsor naming "AD109"
First trial start
2023
Aug 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AD109", any sponsor or status.
Conditions studied
As listed on its trial records.
- OSA
Largest trials
Live from ClinicalTrials.gov: studies naming "AD109" as an intervention, largest first.
- Continuation Protocol for Obstructive Sleep Apnea (OSA)Pivotal-lookingEnrolling by invitation
ApnimedIndustry
NCT06566820 · 1,280 participants (planned) · Start Jul 3, 2024 · Primary completion Jun 30, 2026
Drug: Aroxybutynin and Atomoxetine · For: OSA
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Chandler, Arizona · 99 sites in all
- Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)Pivotal-lookingCompleted
ApnimedIndustry
NCT05811247 · 660 participants · Start Aug 28, 2023 · Primary completion May 7, 2025
Drug: AD109; Placebo · For: OSA
Sites: Birmingham, Alabama; Chandler, Arizona; Little Rock, Arkansas · 64 sites in all
- Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)Pivotal-lookingCompleted
ApnimedIndustry
NCT05813275 · 646 participants · Start Sep 16, 2023 · Primary completion Mar 10, 2025
Drug: AD109; Placebo · For: OSA
Sites: Tuscaloosa, Alabama; Mesa, Arizona; Phoenix, Arizona · 73 sites in all
- Parallel Arm Trial of AD109 and AD504 In Patients With OSAPivotal-lookingCompleted
ApnimedIndustry
NCT05071612 · 294 participants · Start Nov 29, 2021 · Primary completion Jul 20, 2022
Drug: AD109; AD504 and 2 more · For: OSA - Obstructive Sleep Apnea
Sites: Los Angeles, California; San Diego, California; Santa Ana, California · 25 sites in all
ApnimedIndustry
NCT04580394 · 60 participants · Start Oct 27, 2020 · Primary completion May 28, 2021
Drug: AD109; Atomoxetine and 2 more · For: Obstructive Sleep Apnea
Sites: Little Rock, Arkansas; Pomona, California; New Haven, Connecticut · 7 sites in all
ApnimedIndustry
NCT06400615 · 40 participants · Start May 20, 2024 · Primary completion Dec 26, 2024
Drug: AD109 · For: OSA
Sites: Anniston, Alabama; Jacksonville, Florida; Monroe, North Carolina · 4 sites in all
- A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091Completed
Addpharma Inc.Industry
NCT05128591 · 38 participants · Start Nov 9, 2021 · Primary completion Dec 31, 2021
Drug: Rivaroxaban 18mg Oral Tablet; Rivaroxaban 20 MG Oral Tablet · For: Embolism and Thrombosis
Sites: Seoul, South Korea
ApnimedIndustry
NCT04631107 · 32 participants · Start Dec 22, 2020 · Primary completion May 31, 2021
Drug: AD109 dose1- A; AD109 dose2- B and 1 more · For: Obstructive Sleep Apnea
Sites: San Diego, California; Atlanta, Georgia; Philadelphia, Pennsylvania
Newest research
PubMed records naming it or its code names, newest first.
- The pharmacological frontier in obstructive sleep apnoea: From pathophysiologic endotypes to precision medicine.
Kumar H, Tripathi A, Gautam S, et al. · Lung India 2026
- Content validity and clinically meaningful change on patient-reported outcome measures for use in obstructive sleep apnea.
Ojile JM, Yu KS, Farkas R, et al. · Sleep Med 2026
- Precision Pharmacotherapy for Obstructive Sleep Apnea: Matching Targeted Drugs to Patient Endophenotypes.
Oh J, Choi JH · Pharmaceuticals (Basel) 2026
- Targeting Hypoglossal Neurobiology in the Treatment of Obstructive Sleep Apnea: The Emergence of Aroxybutynin-Atomoxetine (AD109).
Wong S, Kendzerska T, Mak MSB · Brain Sci 2026
- Mechanism-directed pharmacotherapy in obstructive sleep apnea: insights from aroxybutynin/atomoxetine (AD109) intervention in the SynAIRgy trial.
Mehra R, Mokhlesi B · Am J Respir Crit Care Med 2026
- Mechanisms of upper airway muscle control in sleep reveal therapeutic targets for obstructive sleep apnea.
Horner RL, Wellman DA, Sands SA, et al. · Am J Respir Cell Mol Biol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.